This project provides a group of new functions to calculate
    the outputs of the two main components of the Canadian Forest Fire
    Danger Rating System (CFFDRS) Van Wagner and Pickett (1985)
    <https://ostrnrcan-dostrncan.canada.ca/entities/publication/29706108-2891-4e5d-a59a-a77c96bc507c>) at various time
    scales: the Fire Weather Index (FWI) System Wan Wagner (1985)
    <https://ostrnrcan-dostrncan.canada.ca/entities/publication/d96e56aa-e836-4394-ba29-3afe91c3aa6c> and the Fire Behaviour
    Prediction (FBP) System Forestry Canada Fire Danger Group (1992)
    <https://cfs.nrcan.gc.ca/pubwarehouse/pdfs/10068.pdf>. Some functions
    have two versions, table and raster based.

The Citation File Format version 1.2.0
    <doi:10.5281/zenodo.5171937> is a human and machine readable file
    format which provides citation metadata for software. This package
    provides core utilities to generate and validate this metadata.

Facilitates the identification of counterfactual queries in
 structural causal models via the ID* and IDC* algorithms
 by Shpitser, I. and Pearl, J. (2007, 2008) <arXiv:1206.5294>, 
 <https://jmlr.org/papers/v9/shpitser08a.html>. 
 Provides a simple interface for defining causal diagrams and counterfactual 
 conjunctions. Construction of parallel worlds graphs and counterfactual graphs 
 is carried out automatically based on the counterfactual query and the causal 
 diagram. See Tikka, S. (2023) <doi:10.32614/RJ-2023-053> for a tutorial of 
 the package.

Provides methods and functions to implement a Recommendation 
    System based on Collaborative Filtering Methodology. 
    See Aggarwal (2016) <doi:10.1007/978-3-319-29659-3> for an overview.

Allows clinicians to predict survival probabilities over the next two years for cystic fibrosis patients, based on the clinical prediction models published in Stanojevic et al. (2019) <doi:10.1183/13993003.00224-2019>.

In phase I clinical trials, the primary objective is to ascertain the maximum tolerated dose (MTD) corresponding to a specified target toxicity rate. The subsequent phase II trials are designed to examine the potential efficacy of the drug based on the MTD obtained from the phase I trials, with the aim of identifying the optimal biological dose (OBD). The 'CFO' package facilitates the implementation of dose-finding trials by utilizing calibration-free odds type (CFO-type) designs. Specifically, it encompasses the calibration-free odds (CFO) (Jin and Yin (2022) <doi:10.1177/09622802221079353>), randomized CFO (rCFO), precision CFO (pCFO), two-dimensional CFO (2dCFO) (Wang et al. (2023) <doi:10.3389/fonc.2023.1294258>), time-to-event CFO (TITE-CFO) (Jin and Yin (2023) <doi:10.1002/pst.2304>), fractional CFO (fCFO), accumulative CFO (aCFO), TITE-aCFO, and f-aCFO (Fang and Yin (2024) <doi: 10.1002/sim.10127>). It supports phase I/II trials for the CFO design and only phase I trials for the other CFO-type designs. The ‘CFO' package accommodates diverse CFO-type designs, allowing users to tailor the approach based on factors such as dose information inclusion, handling of late-onset toxicity, and the nature of the target drug (single-drug or drug-combination). The functionalities embedded in 'CFO' package include the determination of the dose level for the next cohort, the selection of the MTD for a real trial, and the execution of single or multiple simulations to obtain operating characteristics. Moreover, these functions are equipped with early stopping and dose elimination rules to address safety considerations. Users have the flexibility to choose different distributions, thresholds, and cohort sizes among others for their specific needs. The output of the 'CFO' package can be summary statistics as well as various plots for better visualization. An interactive web application for CFO is available at the provided URL.